MDM2, MDMX and p53 in oncogenesis and cancer therapy

Cited by (998)

Items 401–500 of 998

1. Rational design and synthesis of 1,5-disubstituted tetrazoles as potent inhibitors of the MDM2-p53 interaction
   Ewa Surmiak, Constantinos G. Neochoritis, Bogdan Musielak, Aleksandra Twarda‐Clapa, Katarzyna Kurpiewska, Grzegorz Dubin, Carlos Jaime Camacho, Tad A. Holak, Alexander S. S. Dömling · 2016 · European Journal of Medicinal Chemistry
2. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers
   Aaron N. Hata, Steve C. Rowley, Hannah L. Archibald, María Gomez‐Caraballo, F M Siddiqui, Fei Ji, Joonil Jung, Mark E. Light, J S Lee, Laurent Debüssche et al. · 2017 · Oncogene
3. Noncoding RNA in NK cells
   Chuan He Yang, Chongyang Shen, Ting Feng, Hong Li · 2018 · Journal of Leukocyte Biology
4. MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism
   Koki Ueda, Rajni Kumari, Emily Schwenger, Justin C. Wheat, Oliver Bohorquez, Swathi-Rao Narayanagari, Samuel J. Taylor, Luis A. Carvajal, Kith Pradhan, Boris Bartholdy et al. · 2021 · Cancer Cell
5. IDO1 plays a tumor-promoting role via MDM2-mediated suppression of the p53 pathway in diffuse large B-cell lymphoma
   Chengtao Sun, Mengzhen Li, Lian Zhang, Feifei Sun, Huimou Chen, Yanjie Xu, Yingxia Lan, Li Zhang, Suying Lü, Jia Zhu et al. · 2022 · Cell Death and Disease
6. mTOR inhibitors blunt the p53 response to nucleolar stress by regulating RPL11 and MDM2 levels
   Kaveh M. Goudarzi, Monica Nistér, Mikael S. Lindström · 2014 · Cancer Biology & Therapy
7. Down‐regulation of 5S rRNA by miR‐150 and miR‐383 enhances c‐Myc–rpL11 interaction and inhibits proliferation of esophageal squamous carcinoma cells
   Xinyu Wang, Yanli Ren, Zhiqiong Wang, Xiangyu Xiong, Sichong Han, Wenting Pan, Hongwei Chen, Liqing Zhou, Changchun Zhou, Qipeng Yuan et al. · 2015 · FEBS Letters
8. Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells
   Mahadev Rao, Scott M. Atay, Vivek Shukla, Young Ki Hong, Trevor C. Upham, Robert Taylor Ripley, Julie A. Hong, Mary F. Zhang, Emily S. Reardon, Patricia A. Fetsch et al. · 2015 · Clinical Cancer Research
9. How Chemical Synthesis of Ubiquitin Conjugates Helps To Understand Ubiquitin Signal Transduction
   Dharjath S. Hameed, Ayşegül Sapmaz, Huib Ovaa · 2016 · Bioconjugate Chemistry
10. MDM2 mediates fibroblast activation and renal tubulointerstitial fibrosis via a p53-independent pathway
    Chen Ye, Hui Tang, Zheng Zhao, Chun‐Tao Lei, Chaoqun You, Jiao Zhang, Pan Gao, Fang-Fang He, Shan Chen, Yumei Wang et al. · 2017 · American Journal of Physiology-Renal Physiology
11. Friend or Foe: MicroRNAs in the p53 network
    Zhenghua Luo, Ri Cui, Esmerina Tili, Carlo Maria Croce · 2018 · Cancer Letters
12. MicroRNA-29b-2-5p inhibits cell proliferation by directly targeting Cbl-b in pancreatic ductal adenocarcinoma
    Ce Li, Qian Dong, Xiaofang Che, Ling Xu, Zhi Li, Yibo Fan, Kezuo Hou, Shuo Wang, Jinglei Qu, Lu Xu et al. · 2018 · BMC Cancer
13. An Air–Liquid Interface Organ-Level Lung Microfluidics Platform for Analysis on Molecular Mechanisms of Cytotoxicity Induced by Cancer-Causing Fine Particles
    Lulu Zheng, Heng Dong, Wang Zhao, Xinlian Zhang, Xiaoxiao Duan, Hao Zhang, Sixiu Liu, Guodong Sui · 2019 · ACS Sensors
14. MDM2 promotes epithelial–mesenchymal transition through activation of Smad2/3 signaling pathway in lung adenocarcinoma
    Yong Tang, Yiwen Xuan, Guibin Qiao, Zhu’an Ou, Zhe He, Qihang Zhu, Ming Liao, Guilin Yin · 2019 · OncoTargets and Therapy
15. Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
    Zuzana Mrkvová, Stjepan Uldrijan, Antonio R. Pombinho, Petr Bartůněk, Iva Slaninová · 2019 · Molecules
16. Long Non-coding RNA SNHG12 Functions as a Competing Endogenous RNA to Regulate MDM4 Expression by Sponging miR-129-5p in Clear Cell Renal Cell Carcinoma
    Zhipeng Wu, Dongming Chen, Kai Wang, Changchun Cao, Xianlin Xu · 2019 · Frontiers in Oncology
17. GLIS2 promotes colorectal cancer through repressing enhancer activation
    Jie Yao, Pin‐Ji Lei, Qinglan Li, Ji Chen, Shan‐Bo Tang, Qiong Xiao, Xiang Lin, Xiang Wang, Lianyun Li, Min Wu · 2020 · Oncogenesis
18. Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphoma
    Man Nie, Likun Du, Weicheng Ren, Julia Joung, Xiaofei Ye, Xi Shi, Sibel Ciftci, Dongbing Liu, Kui Wu, Feng Zhang et al. · 2021 · Cell Death and Disease
19. MDM2 E3 ligase activity is essential for p53 regulation and cell cycle integrity
    Meenalakshmi Chinnam, Chao Xu, Rati Lama, Xiaojing Zhang, Carlos D. Cedeno, Yanqing Wang, Aimee B. Stablewski, David W. Goodrich, Xinjiang Wang · 2022 · PLoS Genetics
20. Hydrophobic tag tethering degrader as a promising paradigm of protein degradation: Past, present and future perspectives
    Si Ha, Jiacheng Zhu, Hua Xiang, Guoshun Luo · 2023 · Chinese Chemical Letters
21. Inhibition of P53-murine double minute 2 (MDM2) interactions with 3,3′-spirocyclopentene oxindole derivatives
    Gicquel, Maxime, Gomez, Catherine, Garcia Alvarez, Maria Concepcion, Pamlard, Olivier, Guérineau, Vincent, Jacquet, Eric, Bignon, Jérôme, Voituriez, Arnaud, Marinetti, Angela · 2018 · Journal of Medicinal Chemistry
22. Spirooxadiazoline oxindoles with promising in vitro antitumor activities
    Carlos J. A. Ribeiro, Joana D. Amaral, Cecília M. P. Rodrigues, Rui Moreira, Maria M. M. Santos · 2015 · MedChemComm
23. Ubiquitination in melanoma pathogenesis and treatment
    Jinyuan Ma, Weinan Guo, Chunying Li · 2017 · Cancer Medicine
24. The role of E3 ubiquitin ligase HECTD3 in cancer and beyond
    Qiuyun Jiang, Fubing Li, Zhuo Cheng, Yanjie Kong, Ceshi Chen · 2019 · Cellular and Molecular Life Sciences
25. Regulation of E3 ubiquitin ligases by homotypic and heterotypic assembly
    Vishnu Balaji, Thorsten Hoppe · 2020 · F1000Research
26. Radiation-Induced Bystander Response: Mechanism and Clinical Implications
    Keiji Suzuki, Shunichi Yamashita · 2013 · Advances in Wound Care
27. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway
    Yangwei Fan, Mengya Li, Ke Ma, Yuan Hu, Jiayu Jing, Yu Shi, Enxiao Li, Danfeng Dong · 2018 · Cancer Biology & Therapy
28. Constrained α-Helical Peptides as Inhibitors of Protein-Protein and Protein-DNA Interactions
    Siddhartha Roy, Piya Ghosh, Israr Ahmed, Madhumita Chakraborty, Gitashri Naiya, Basusree Ghosh · 2018 · Biomedicines
29. Asrij/OCIAD1 suppresses CSN5-mediated p53 degradation and maintains mouse hematopoietic stem cell quiescence
    Saloni Sinha, Tirath Raj Dwivedi, Roja Yengkhom, Venkata Anudeep Bheemsetty, Takaya Abe, Hiroshi Kiyonari, Krishnaswamy VijayRaghavan, Maneesha S. Inamdar · 2019 · Blood
30. A Thirteen-Gene Expression Signature Predicts Survival of Patients with Pancreatic Cancer and Identifies New Genes of Interest
    Timothy Eric Newhook, Edik Matthew Blais, James M. Lindberg, Sara J. Adair, Wenjun Xin, Jae K. Lee, Jason A. Papin, J. Thomas Parsons, Todd W. Bauer · 2014 · PLoS ONE
31. 1,4,5-Trisubstituted Imidazole-Based p53–MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers
    Aleksandra Twarda‐Clapa, Sylwia Krzanik, Katarzyna Kubica, Katarzyna Guzik, Beata Łabuzek, Constantinos G. Neochoritis, Kareem Khoury, Kaja Kowalska, Mirosława Czub, Grzegorz Dubin et al. · 2017 · Journal of Medicinal Chemistry
32. Circular RNA circ_0102049 promotes cell progression as ceRNA to target MDM2 via sponging miR-1304-5p in osteosarcoma
    Yan Jin, Lisen Li, Tongtong Zhu, Guangyao Liu · 2019 · Pathology - Research and Practice
33. Nutlin-Induced Apoptosis Is Specified by a Translation Program Regulated by PCBP2 and DHX30
    Dario Rizzotto, Sara Zaccara, Annalisa Rossi, Matthew D. Galbraith, Zdeněk Andrysík, Ahwan Pandey, Kelly D. Sullivan, Alessandro Quattrone, Joaquin Maximiliano Espinosa, Erik Dassi et al. · 2020 · Cell Reports
34. Identification of a druggable protein–protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1
    Xin Tong, Dandan Xu, Rama K. Mishra, Ryan Jones, Leyu Sun, Gary E. Schiltz, Jie Liao, Guang‐Yu Yang · 2020 · Journal of Biological Chemistry
35. Serum anti-MDM2 and anti-c-Myc autoantibodies as biomarkers in the early detection of lung cancer
    Pei Zhen Li, Jian-Xiang Shi, Li-Ping Dai, Yurong Chai, Hong-Fei Zhang, Mutombo Kankonde, Peggy Kankonde, Bao-Fa Yu, Jian-Ying Zhang · 2016 · OncoImmunology
36. Resistance acquisition to MDM2 inhibitors
    Cinatl, Jindrich, Speidel, Daniel, Hardcastle, Ian, Michaelis, Martin · 2014 · Biochemical Society Transactions
37. FISH Diagnostic Assessment of MDM2 Amplification in Liposarcoma: Potential Pitfalls and Troubleshooting Recommendations
    Alessandro Gambella, Luca Bertero, Milena Rondón‐Lagos, Ludovica Verdun di Cantogno, Nelson Rangel, Chiara Pitino, Alessia Andrea Ricci, Luca Mangherini, Isabella Castellano, Paola Cassoni · 2023 · International Journal of Molecular Sciences
38. Oxidative Stress, Transfer RNA Metabolism, and Protein Synthesis
    Yasutoshi Akiyama, Pavel V. Ivanov · 2023 · Antioxidants and Redox Signaling
39. Magnetic poly(glycidyl methacrylate) microspheres for protein capture
    J. (Jana) Koubková, Petr Müller, Helena Hlídková, Zdeněk Plichta, Vladimír Proks, Bořivoj Vojtěšek, Daniel Horák · 2014 · New Biotechnology
40. MiR-1205 functions as a tumor suppressor by disconnecting the synergy between KRAS and MDM4/E2F1 in non-small cell lung cancer.
    Hong Yan, Xiaoying Chen, Yu Li, Lei Fan, Yusi Tai, Yang Zhou, Yuxiang Chen, Xinming Qi, Ruimin Huang, Jin Ren · 2019 · Europe PMC (PubMed Central)
41. Mdm2 enhances ligase activity of parkin and facilitates mitophagy
    Seunghyi Kook, Xuanzhi Zhan, Kimberly C. Thibeault, Mohamed Rafiuddin Ahmed, Vsevolod V. Gurevich, Eugenia V. Gurevich · 2020 · Scientific Reports
42. Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma
    Xiangling Feng, Jiaojiao Guo, Gang An, Yangbowen Wu, Zhenhao Liu, Bin Meng, Nihan He, Xinying Zhao, Shilian Chen, Yinghong Zhu et al. · 2022 · Advanced Science
43. MDM2 binds and ubiquitinates PARP1 to enhance DNA replication fork progression
    Celeste Giansanti, Valentina Manzini, Antje Dickmanns, Achim Dickmanns, Maria Dilia Palumbieri, Andrea Sanchi, Simon Maria Kienle, Sonja Rieth, Martin Scheffner, Massimo Lopes et al. · 2022 · Cell Reports
44. Antitumor effect of melatonin on breast cancer in experimental models: A systematic review
    Pablo Igor Ribeiro Franco, José Rodrigues do Carmo Neto, Anália Cirqueira Milhomem, Juliana Reis Machado, Marina Pacheco Miguel · 2022 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
45. Novel isatin-derived molecules activate p53 via interference with Mdm2 to promote apoptosis
    Olga Fedorova, Alexandra A. Daks, Varvara Petrova, Alexey Petukhov, Larissa Lezina, Oleg Y. Shuvalov, Pavel B. Davidovich, Daria V. Kriger, Ekaterina V. Lomert, Dmitri Tentler et al. · 2018 · Cell Cycle
46. Structural States of Hdm2 and HdmX: X‐ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes
    Joerg A. Kallen, Aude Izaac, Suzanne Chau, Emmanuelle Wirth, Joseph G. Schoepfer, Robert Mah, Achim Schlapbach, Stefan Stutz, Andrea Vaupel, Vito Guagnano et al. · 2019 · ChemMedChem
47. Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
    Maryam Zanjirband, Soheila Rahgozar · 2019 · Current Drug Targets
48. Protoporphyrin IX is a dual inhibitor of p53/MDM2 and p53/MDM4 interactions and induces apoptosis in B-cell chronic lymphocytic leukemia cells
    Liren Jiang, Natasha Malik, Pilar Acedo, Joanna Zawacka‐Pankau · 2019 · Cell Death Discovery
49. Neurogenic differentiation factor 1 promotes colorectal cancer cell proliferation and tumorigenesis by suppressing the p53/p21 axis
    Ke Lei, Wenfang Li, Can Huang, Yanjun Li, Leader Alfason, Hezhao Zhao, Makoto Miyagishi, Shourong Wu, Vivi Kasim · 2019 · Cancer Science
50. The transcription factor PBX3 promotes tumor cell growth through transcriptional suppression of the tumor suppressor p53
    Wenfang Li, Arin Herkilini, Yu Rong Tang, Ping Cheong Huang, Guanbin Song, Makoto Miyagishi, Vivi Kasim, Shourong Wu · 2021 · Acta Pharmacologica Sinica
51. Structure-Based Discovery of MDM2/4 Dual Inhibitors that Exert Antitumor Activities against MDM4-Overexpressing Cancer Cells
    Shiyan Zhang, Ziqin Yan, Yafang Li, Yang Gong, Xilin Lyu, Jianfeng Lou, Daizhou Zhang, Xiangjing Meng, Yujun Zhao · 2022 · Journal of Medicinal Chemistry
52. Exposure to High-Dose Diesel Exhaust Particles Induces Intracellular Oxidative Stress and Causes Endothelial Apoptosis in Cultured In Vitro Capillary Tube Cells
    Chia‐Yi Tseng, Jhih-Syuan Wang, Yu‐Jung Chang, Jing-Fen Chang, Ming‐Wei Chao · 2014 · Cardiovascular Toxicology
53. Zinc finger protein ZBTB20 promotes cell proliferation in non‐small cell lung cancer through repression of FoxO1
    Jungang Zhao, Kaiming Ren, Jun Tang · 2014 · FEBS Letters
54. Combined treatment with vitamin C and sulindac synergistically induces p53- and ROS-dependent apoptosis in human colon cancer cells
    Eun-Yeung Gong, Yu Jin Shin, Ih-Yeon Hwang, Jeong Hee Kim, Seung-Mi Kim, Jai-Hee Moon, Jae-Sik Shin, Dae‐Hee Lee, Dae Young Hur, Dong-Hoon Jin et al. · 2016 · Toxicology Letters
55. A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein
    Georgios Valianatos, Barbora Valčíková, Kateřina Growková, Amandine Verlande, Jitka Mlčochová, Lenka Radová, Monika Štětková, Michaela Vyhnakova, Ondřej Slabý, Stjepan Uldrijan · 2017 · PLoS ONE
56. Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets
    Elke Tatjana Aristizabal Prada, Christoph Josef Auernhammer · 2017 · Endocrine Connections
57. The role of proteasomes in tumorigenesis
    Xiangyi Zhou, Ruqing Xu, Yue Wu, Li Zhou, Tingxiu Xiang · 2023 · Genes & Diseases
58. Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia
    Zhiyu Zhang, Jiayi Huang, Zhibo Zhang, Hongjie Shen, Xiaowen Tang, Depei Wu, Xiebing Bao, Guoqiang Xu, Suning Chen · 2024 · Biomarker Research
59. RETRA exerts anticancer activity in Ewing’s sarcoma cells independent of their TP53 status
    Jürgen Sonnemann, Désirée Grauel, Lisa Blümel, Julia Hentschel, Christian Marx, Annelie Blumrich, Katharina Focke, Sabine Becker, Susan Wittig, Sandra Schinkel et al. · 2015 · European Journal of Cancer
60. Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA
    Jiang‐Jiang Qin, Wei Wang, Sukesh Voruganti, Hui Wang, Weidong Zhang, Ruiwen Zhang · 2015 · Oncotarget
61. MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance
    Ulrich H. Weidle, DANIELA SCHMID, Fabian Birzele, Ulrich Brinkmann · 2019 · Cancer Genomics & Proteomics
62. SATB1 Promotes Pancreatic Cancer Growth and Invasion Depending on MYC Activation
    Zheng Chen, Zengliang Li, Wěi Li, Yang Zong, Yi Zhu, Yi Miao, Zekuan Xu · 2015 · Digestive Diseases and Sciences
63. SUV39H1/H3K9me3 attenuates sulforaphane-induced apoptotic signaling in PC3 prostate cancer cells
    Gregory W. Watson, Samanthi I. Wickramasekara, Zoraya Palomera‐Sánchez, Chelsea Black, Claudia S. Maier, D E Williams, Roderick H. Dashwood, Emily Ho · 2014 · Oncogenesis
64. HMGA2 promotes intestinal tumorigenesis by facilitating MDM2‐mediated ubiquitination and degradation of p53
    Yuhong Wang, Lin Tao Hu, Jian Wang, Xiangwei Li, Sana Sahengbieke, Jingjing Wu, Maode Lai · 2018 · The Journal of Pathology
65. Recombinant Butelase-Mediated Cyclization of the p53-Binding Domain of the Oncoprotein MdmX-Stabilized Protein Conformation as a Promising Model for Structural Investigation
    Ni Pi, Meng Gao, Xiyao Cheng, Huili Liu, Zhengkun Kuang, Zixin Yang, Jing Yang, Bailing Zhang, Yao Chen, Sen Liu et al. · 2019 · Biochemistry
66. CDK9 inhibitors reactivate p53 by downregulating iASPP
    Jiale Wu, Ying Liang, Yun Tan, Yigang Tang, Huaxin Song, Zhengyuan Wang, Yuntong Li, Min M. Lu · 2019 · Cellular Signalling
67. Long non‑coding RNA PCAT6 promotes the development of osteosarcoma by increasing MDM2 expression
    Xiliang Guan, Yufen Xu, Ju-fen Zheng · 2020 · Oncology Reports
68. An overview of PROTACs targeting MDM2 as a novel approach for cancer therapy
    Huiwen Li, Xinhui Cai, Xiaoyu Yang, Xuan Zhang · 2024 · European Journal of Medicinal Chemistry
69. Proteomic signatures associated with p53 mutational status in lung adenocarcinoma
    Ayumu Taguchi, Oliver Delgado, Müge Çeliktaş, Hiroyuki Katayama, Hong Wang, Adi F. Gazdar, Samir Hanash · 2014 · PROTEOMICS
70. Ubiquitin proteasome system-mediated degradation of synaptic proteins: An update from the postsynaptic side
    Nien‐Pei Tsai · 2014 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
71. Salvation of the fallen angel: Reactivating mutant p53
    Li Yang, Zhuoyi Wang, Yuchen Chen, Robert B. Petersen, Ling Zheng, Kun Huang · 2019 · British Journal of Pharmacology
72. Oridonin induces Mdm2‐p60 to promote p53‐mediated apoptosis and cell cycle arrest in neuroblastoma
    Hanqing Zhu, Chao Zhang, Guo Zhu-ying, Junmei Yang, Jiahui Guo, Chen Chen, Qianghua Yao, Feng Liu, Quan‐Wu Zhang, Feng‐Hou Gao · 2019 · Cancer Medicine
73. Ubiquitin-Like Protein UBD Promotes Cell Proliferation in Colorectal Cancer by Facilitating p53 Degradation
    Hongbin Su, Mengdi Qin, Qiang Liu, Bo Jin, Xianjun Shi, Zheng Xiang · 2021 · Frontiers in Oncology
74. MDM2-Driven Ubiquitination Rapidly Removes p53 from Its Cognate Promoters
    Kester Mo Henningsen, Valentina Manzini, Anna Magerhans, Sabrina Gerber, Matthias Dobbelstein · 2021 · Biomolecules
75. Coupled deglycosylation-ubiquitination cascade in regulating PD-1 degradation by MDM2
    Zhen Wu, Zhijie Cao, Han Yao, Xiaojun Yan, Wenbin Xu, Mi Zhang, Zishan Jiao, Zijing Zhang, Jianyuan Chen, Yajing Liu et al. · 2023 · Cell Reports
76. The role of alternative pre-mRNA splicing in cancer progression
    Sunkyung Choi, Namjoon Cho, Eun-Mi Kim, Kee Kwang Kim · 2023 · Cancer Cell International
77. Small molecule therapeutics targeting F-box proteins in cancer
    Yuan Liu, Rama K. Mallampalli · 2015 · Seminars in Cancer Biology
78. Design, synthesis and biological evaluation of novel antitumor spirotetrahydrothiopyran–oxindole derivatives as potent p53-MDM2 inhibitors
    Changjin Ji, Shengzheng Wang, Shuqiang Chen, Shipeng He, Yan Jiang, Zhenyuan Miao, Jian Li, Chunquan Sheng · 2017 · Bioorganic & Medicinal Chemistry
79. Simultaneous Targeting of RGD-Integrins and Dual Murine Double Minute Proteins in Glioblastoma Multiforme
    Francesco Merlino, Simona Daniele, Valeria La Pietra, Salvatore Di Maro, Francesco Saverio Di Leva, Diego Brancaccio, Stefano Tomassi, Stefano Giuntini, Linda Cerofolini, Marco Fragai et al. · 2018 · Journal of Medicinal Chemistry
80. SMYD3 promotes epithelial ovarian cancer metastasis by downregulating p53 protein stability and promoting p53 ubiquitination
    Liwei Zhang, Yue Jin, Hao Yang, Yu Li, Chao Wang, Yongheng Shi, Yu Wang · 2019 · Carcinogenesis
81. Lipoic Acid Synergizes with Antineoplastic Drugs in Colorectal Cancer by Targeting p53 for Proteasomal Degradation
    Carina Neitzel, Nina Seiwert, Anja Göder, Erika Diehl, Carina Weber, Georg Nagel, Svenja Stroh, Birgit Rasenberger, Markus Christmann, Jörg Fahrer · 2019 · Cells
82. KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
    Yogesh K. Chutake, Michele Mayo, Nancy Dumont, Jessica Filiatrault, Susanne B. Breitkopf, Patricia Cho, Dapeng Chen, Vaishali S. Dixit, William R. Proctor, Eric W. Kuhn et al. · 2024 · Molecular Cancer Therapeutics
83. MDMX exerts its oncogenic activity via suppression of retinoblastoma protein
    Hong Zhang, Liang Hu, W Qiu, Tiantian Deng, Yong Zhang, Johann S. Bergholz, Z-X Xiao · 2015 · Oncogene
84. Macrocyclic peptides as regulators of protein-protein interactions
    Yang Zi Jiang, Hongyi Long, Yu‐Jie Zhu, Yi Zeng · 2018 · Chinese Chemical Letters
85. Alternative Mechanisms of p53 Action During the Unfolded Protein Response
    Leïla T. S. Fusée, Mónica Marı́n, Robin Fåhræus, Ignacio López · 2020 · Cancers
86. Competition NMR for Detection of Hit/Lead Inhibitors of Protein–Protein Interactions
    Bogdan Musielak, Weronika Janczyk, Ismael Rodríguez, Jacek Plewka, Dominik Sala, Katarzyna Magiera‐Mularz, Tad A. Holak · 2020 · Molecules
87. Cucurbitacin-E Inhibits Multiple Cancer Cells Proliferation Through Attenuation of Wnt/β-Catenin Signaling
    Hui Feng, Li Zang, Zhen-Xia Zhao, Quancheng Kan · 2014 · Cancer Biotherapy and Radiopharmaceuticals
88. Efficient Reactivation of p53 in Cancer Cells by a Dual MdmX/Mdm2 Inhibitor
    Lingyun Qin, Fei Yang, Cindy Ke Zhou, Yao Chen, Hua‐Shan Zhang, Zhengding Su · 2014 · Journal of the American Chemical Society · Retracted
89. Stapled Peptides: Providing the Best of Both Worlds in Drug Development
    Xiayang Xie, Lixia Gao, Austin Young Shull, Yong Teng · 2016 · Future Medicinal Chemistry
90. Surface Plasmon Resonance Sensing of Biorecognition Interactions within the Tumor Suppressor p53 Network
    Ilaria Moscetti, Salvatore Cannistraro, Anna Rita Bizzarri · 2017 · Sensors
91. Cyclophilin B induces chemoresistance by degrading wild‐type p53 via interaction with MDM2 in colorectal cancer
    Tae Gyu Choi, Minh Nam Nguyen, Jieun Kim, Yong Hwa Jo, Miran Jang, Ngoc Ngo Yen Nguyen, Hyeong Rok Yun, Wonchae Choe, Insug Kang, Joohun Ha et al. · 2018 · The Journal of Pathology
92. p53 inhibition by MDM2 in human pterygium
    Di Cao, Tsz Kin Ng, Yolanda Wong Ying Yip, Alvin Lerrmann Young, Chi Pui Pang, Wai Kit Chu, Vishal Jhanji · 2018 · Experimental Eye Research
93. RBM10, a New Regulator of p53
    Ji Hoon Jung, Hyemin Lee, Shelya X. Zeng, Hua Lu · 2020 · Cells
94. MDM2andCDK4amplifications are rare events in salivary duct carcinomas
    Inga Grünewald, Marcel Trautmann, Alina Busch, Larissa Bauer, Sebastian Huss, Petra Schweinshaupt, Claudia Vollbrecht, Margarete Odenthal, Alexander Quaas, Reinhard Büttner et al. · 2016 · Oncotarget
95. Imidazoline scaffold in medicinal chemistry: a patent review (2012–2015)
    Franciszek Sa̧czewski, Anita Kornicka, Łukasz Balewski · 2016 · Expert Opinion on Therapeutic Patents
96. Fast NMR‐Based Determination of the 3D Structure of the Binding Site of Protein–Ligand Complexes with Weak Affinity Binders
    Marielle Aulikki Wälti, Roland Riek, Julien Orts · 2017 · Angewandte Chemie International Edition
97. Activation of p53 and destabilization of androgen receptor by combinatorial inhibition of MDM2 and MDMX in prostate cancer cells
    Harman Chopra, Zara Ahmad Khan, Jamie Contreras, Herui Wang, Abanob Sedrak, Yan Yu Zhu · 2017 · Oncotarget
98. Epigenetic mechanisms behind cellular sensitivity to DNA damage
    Amanda K. Williamson, Zijing Zhu, Zhi-Min Yuan · 2018 · Cell Stress
99. The Nuclear Farnesoid X Receptor Reduces p53 Ubiquitination and Inhibits Cervical Cancer Cell Proliferation
    Xiaohua Huang, Bin Wang, Runji Chen, Shuping Zhong, Fenfei Gao, Yanmei Zhang, Yongdong Niu, Congzhu Li, Ganggang Shi · 2021 · Frontiers in Cell and Developmental Biology
100. DAB2IP suppresses tumor malignancy by inhibiting GRP75-driven p53 ubiquitination in colon cancer
     Shengjie Feng, Qingwen Huang, Jiao Deng, Weiyi Jia, Jianping Gong, Daxing Xie, Jie Shen, Liang Liu · 2022 · Cancer Letters